SE0201194D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0201194D0
SE0201194D0 SE0201194A SE0201194A SE0201194D0 SE 0201194 D0 SE0201194 D0 SE 0201194D0 SE 0201194 A SE0201194 A SE 0201194A SE 0201194 A SE0201194 A SE 0201194A SE 0201194 D0 SE0201194 D0 SE 0201194D0
Authority
SE
Sweden
Prior art keywords
sup
sub
alkyl
new compounds
nitro
Prior art date
Application number
SE0201194A
Other languages
English (en)
Inventor
Stefan Berg
Sven Hellberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201194A priority Critical patent/SE0201194D0/sv
Publication of SE0201194D0 publication Critical patent/SE0201194D0/sv
Priority to CA002480451A priority patent/CA2480451A1/en
Priority to PCT/SE2003/000616 priority patent/WO2003089419A1/en
Priority to EP03721210A priority patent/EP1499601A1/en
Priority to US10/510,846 priority patent/US20050119321A1/en
Priority to JP2003586140A priority patent/JP2005526835A/ja
Priority to AU2003224547A priority patent/AU2003224547A1/en
Priority to US11/430,061 priority patent/US20060194854A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
SE0201194A 2002-04-19 2002-04-19 New compounds SE0201194D0 (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE0201194A SE0201194D0 (sv) 2002-04-19 2002-04-19 New compounds
CA002480451A CA2480451A1 (en) 2002-04-19 2003-04-15 New 2-substituted -1,3-thiazole compounds
PCT/SE2003/000616 WO2003089419A1 (en) 2002-04-19 2003-04-15 New 2-substituted -1,3-thiazole compounds
EP03721210A EP1499601A1 (en) 2002-04-19 2003-04-15 New 2-substituted -1,3-thiazole compounds
US10/510,846 US20050119321A1 (en) 2002-04-19 2003-04-15 2-substituted-1,3-thiazole compounds
JP2003586140A JP2005526835A (ja) 2002-04-19 2003-04-15 新規な２−置換−１，３−チアゾール化合物
AU2003224547A AU2003224547A1 (en) 2002-04-19 2003-04-15 New 2-substituted -1,3-thiazole compounds
US11/430,061 US20060194854A1 (en) 2002-04-19 2006-05-08 New 2-substituted - 1,3-thiazole compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201194A SE0201194D0 (sv) 2002-04-19 2002-04-19 New compounds

Publications (1)

Publication Number Publication Date
SE0201194D0 true SE0201194D0 (sv) 2002-04-19

Family

ID=20287631

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201194A SE0201194D0 (sv) 2002-04-19 2002-04-19 New compounds

Country Status (7)

Country Link
US (2) US20050119321A1 (sv)
EP (1) EP1499601A1 (sv)
JP (1) JP2005526835A (sv)
AU (1) AU2003224547A1 (sv)
CA (1) CA2480451A1 (sv)
SE (1) SE0201194D0 (sv)
WO (1) WO2003089419A1 (sv)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524870B2 (en) * 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200808751A (en) * 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
EP1849785A1 (en) * 2006-04-28 2007-10-31 Neuropharma, S.A. N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
ITVA20060041A1 (it) * 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20120010178A1 (en) * 2008-10-21 2012-01-12 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010226857B2 (en) 2009-03-20 2016-07-14 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
EP2632460B1 (en) 2010-09-20 2018-02-28 University of Virginia Patent Foundation Thiophene derivatives for use in the treatment of tuberculosis
KR101445175B1 (ko) * 2011-09-16 2014-10-06 연세대학교 산학협력단 중간엽 줄기세포의 혈관내피세포로의 분화 유도를 위한 티아졸기를 함유하는 우레아 화합물
WO2017027984A1 (en) * 2015-08-20 2017-02-23 Simon Fraser University Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy
US20190177696A1 (en) 2016-06-16 2019-06-13 Ecole Polytechnique Federale De Lausanne (Epfl) Method for preparing induced hepatic progenitor cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2755285A (en) * 1956-07-17 I-xsubstituted
US2988480A (en) * 1952-10-21 1961-06-13 Merck & Co Inc Therapeutically active compositions
GB771147A (en) * 1954-06-04 1957-03-27 Merck & Co Inc Derivatives of urea
US3523122A (en) * 1969-02-03 1970-08-04 Parke Davis & Co Novel 5-nitro-4-thiazolin-2-ylidene compounds
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
AU2001230026A1 (en) * 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
SE0102440D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compound

Also Published As

Publication number Publication date
US20050119321A1 (en) 2005-06-02
JP2005526835A (ja) 2005-09-08
CA2480451A1 (en) 2003-10-30
AU2003224547A1 (en) 2003-11-03
US20060194854A1 (en) 2006-08-31
EP1499601A1 (en) 2005-01-26
WO2003089419A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
SE0201194D0 (sv) New compounds
HUP0201646A2 (hu) Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
SE0202463D0 (sv) Novel compounds
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
DK0620216T3 (da) Benzamidderivater og deres anvendelse som vasopressinantagonister
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TNSN03110A1 (en) Azaindoles.
UY27368A1 (es) Nuevos compuestos
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
ATE330601T1 (de) Sulfonamide als matrix-metalloproteinase inhibitoren
SE0102055D0 (sv) New Compounds
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
SE0002476D0 (sv) New compounds
AR044175A1 (es) Compuestos de cefemo
DE60316436D1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
DK1412332T3 (da) Quinolinderivater og anvendelse deraf som antitumormidler
DK0871626T3 (da) Triazoloner som apolipoprotein-B syntheseinhibitorer
SE0202461D0 (sv) Novel compounds
SE0301371D0 (sv) New Compounds